Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia
Atherosclerosis-associated chronic inflammation: the outcome of metabolic imbalances or irregular immune responses?
Lomitapide in the long-term real-world management of HOFH – effectiveness, tolerability, and hepatic safety data from the pan-european study
